Comparative Pharmacology
Head-to-head clinical analysis: MPI INDIUM DTPA IN 111 versus PULMOTECH MAA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MPI INDIUM DTPA IN 111 versus PULMOTECH MAA.
MPI INDIUM DTPA IN 111 vs PULMOTECH MAA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Indium In-111 DTPA is a radiopharmaceutical that emits gamma radiation, used for imaging. DTPA chelates indium-111 and, after administration, distributes in the extracellular fluid and is cleared by glomerular filtration, allowing cisternography and renal imaging.
PULMOTECH MAA is a biologic agent that selectively inhibits the interleukin-5 (IL-5) signaling pathway by binding to the IL-5 receptor alpha subunit on the surface of eosinophils, thereby blocking eosinophil maturation, activation, and survival. This reduces eosinophil-mediated inflammation in the airways.
Adult: 18.5 MBq (0.5 mCi) administered intravenously as a single dose for renal imaging.
4 mg IV every 6 hours; administer over 30 minutes.
None Documented
None Documented
Terminal half-life: 2.5-4.0 hours (plasma); prolonged in renal impairment.
Terminal elimination half-life is 12 ± 3 hours. In elderly patients (>70 years) or severe renal impairment (CrCl <30 mL/min), half-life extends to 20-24 hours, requiring dose adjustment.
Renal: 90% within 24 hours via glomerular filtration; minimal biliary/fecal (<5%).
Renal excretion accounts for 65% (20% unchanged, 45% as metabolites); biliary/fecal excretion accounts for 30% (primarily conjugates); 5% exhaled as CO2.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical